The Influences of Chromium Supplementation on Metabolic Status in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease by Farrokhian, A. et al.
The Influences of Chromium Supplementation on Metabolic Status
in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease
Alireza Farrokhian1 & Mina Mahmoodian1 & Fereshteh Bahmani2 & Elaheh Amirani2 & Rana Shafabakhsh2 &
Zatollah Asemi2
Received: 4 May 2019 /Accepted: 14 June 2019 /Published online: 26 June 2019
# Springer Science+Business Media, LLC, part of Springer Nature 2019
Abstract
This investigation was conducted to determine the effects of chromium supplementation on metabolic status in diabetic patients
with coronary heart disease (CHD). This randomized, double-blind, placebo-controlled trial was performed in 64 diabetic
patients with CHD between October 2017 and January 2018. Patients were randomly divided into two groups to obtain either
200 μg chromium (n = 32) or placebo (n = 32) for 12 weeks. Chromium supplementation significantly reduced body weight (−
0.9 ± 1.6 vs. + 0.1 ± 0.8 kg, P = 0.001), BMI (− 0.4 ± 0.7 vs. + 0.1 ± 0.3 kg/m2, P = 0.002), fasting glucose (β − 11.03 mg/dL;
95% CI, − 18.97, − 3.09; P = 0.007), insulin (β − 1.33 μIU/mL; 95% CI, − 1.90, − 0.76; P < 0.001), and insulin resistance (β −
0.44; 95% CI, − 0.62, − 0.25; P < 0.001) and significantly increased insulin sensitivity (β 0.007; 95% CI, 0.003, 0.01; P < 0.001)
compared with the placebo. In addition, taking chromium led to a significant reduction in serum high-sensitivity C-reactive
protein (hs-CRP) (β − 0.49 mg/L; 95% CI, − 0.91, − 0.06; P = 0.02) and plasma malondialdehyde (MDA) levels (β − 0.22
μmol/L; 95%CI, − 0.35, − 0.10; P = 0.001); also, a significant rise in total antioxidant capacity (TAC) (β 84.54 mmol/L; 95%CI,
31.05, 138.02; P = 0.002) was observed in comparison with placebo. Additionally, chromium administration significantly
reduced diastolic blood pressure (DBP) (β − 5.01 mmHg; 95% CI, − 9.04, − 0.97; P = 0.01) compared with the placebo.
Overall, the 12-week supplementation of chromium to diabetic patients with CHD had beneficial impacts on weight, BMI,
glycemic control, hs-CRP, TAC, MDA, and DBP.
Trial Registration www.irct.ir: http://www.irct.ir: IRCT20170513033941N30.
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Introduction
Type 2 diabetes mellitus (T2DM) is a global health concern,
with high morbidity and mortality rates [1]. The predictions
are indicator of a growing burden of diabetes, particularly in
developing countries [1]. T2DM is characterized by hypergly-
cemia, insulin resistance, and dyslipidemia resulting in the
occurrence of chronic inflammation, atherogenesis, and cardi-
ac complications [2]. Based on the available evidence,
coronary heart disease (CHD) is highly prevalent among dia-
betic patients and considered as the major cause of death [3].
In T2DM complicated with CHD, multiple approaches such
as lifestyle modification and pharmacological therapy are used
for the management of glycemic status, atherosclerosis, and
prevention of cardiovascular events [4].
It is proposed that subclinical chromium deficiency may
contribute to glucose intolerance, insulin resistance, and car-
diovascular disease particularly in an aging population [5].
Some observational studies have shown that diabetic and car-
diac patients have reduced chromium levels compared with
healthy individuals [6, 7]. In patients with coronary artery
disease, serum chromium levels were inversely correlated
with glucose levels [8]. In addition, it is indicated that lower
chromium levels in T2DM were associated with insulin resis-
tance and dyslipidemia [9]. Previous evidence demonstrated
that chromium supplementation decreased the risk of T2DM
[10]. Moreover, in a meta-analysis study by Huang et al. [11],
chromium supplementation to diabetic patients improved
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glycemic control and lipid profiles. In addition, we have pre-
viously reported that an 8-week supplementation with chro-
mium significantly reduced biomarkers of inflammation and
oxidative stress in women with polycystic ovary syndrome
(PCOS) [12]. Documented evidence suggested that chromium
supplementation to overweight and obese people significantly
decreased body weight [13]. However, some studies failed to
find any significant improvement in body weight or parame-
ters related to inflammation, glycemic, and lipid control in
patients with metabolic syndrome after chromium supplemen-
tation [14, 15]. In addition, in several meta-analyses, chromi-
um supplementation did not affect or had little effect on serum
lipids or glycemic control was found in people without diabe-
tes [16], patients with T2DM [17], and diabetic patients [18].
Chromium possibly improves glucose homeostasis and in-
sulin sensitivity through the effects on insulin receptors, glu-
cose transporters (GLUT) translocation, and the activity of
different enzymes involved in the insulin signaling cascade
[19]. The increase in energy expenditure and insulin sensitiv-
ity by chromium may involve in weight management [20]. In
addition, chromium exerts anti-inflammatory and antioxida-
tive roles by inhibiting nuclear factor kappa B (NF-kB) acti-
vation and attenuating insulin resistance [21]. Therefore, we
postulated that chromium supplementation may have benefi-
cial effects in subjects with diabetes and CHD. The purpose of
this study was to examine the effects of chromium supplemen-
tation on weight management, glycemic control, lipid profiles,
biomarkers of inflammation, and oxidative stress in subjects
with diabetes and CHD.
Methods
Study Population
The current study was a randomized, double-blind, placebo-
controlled trial, registered in the Iranian registry of clinical
trials (http://www.irct.ir: IRCT20170513033941N30), and
was performed at a cardiology clinic affiliated to Kashan
University of Medical Sciences (KAUMS), Kashan, Iran,
between January 2018 and July 2018. The investigation was
conducted based on the Declaration of Helsinki principals.
The protocol of this study was approved by Research Ethics
Committee, KAUMS, and Iran.Written informed consent was
taken from all patients. Inclusion criteria were as follows:
patients with T2DM, aged 40–85 years old with 2- and 3-
vessel CHD. Diagnosis of T2DM was made according to the
criteria of American Diabetes Association [22]. Furthermore,
diagnosis of CHD was done according to the criteria of
American Heart Association [23]. Patients who had one or
more of the following criteria was considered as having
CHD status: document of at least 50% stenosis in one or more
coronary vessels upon cardiac catheterization assessed by the
angiography, record of myocardial infarction, document of the
exercise-induced ischemia by treadmill electrocardiogram or
nuclear perfusion stress imaging, and a history of coronary
revascularization [23]. Exclusion criteria were consuming
chromium 3 months prior to the intervention, taking antioxi-
dant and/or anti-inflammatory supplements such as vitamin E,
vitamin C, and omega-3 fatty acids, change in type and dosage
of antidiabetic and antilipidemic agents, and having an acute
myocardial infarction, a cardiac surgery in the past 3 months,
or renal or hepatic failure.
Study Design
Participants in each stratum were randomly allocated into two
treatment groups to take either 200 μg chromium as chromi-
um picolinate (21st Century, AZ, USA) or placebo (Barij
Essence, Kashan, Iran) (n = 32 in each group) for 12 weeks.
Due to the lack of evidence about the appropriate dosage of
chromium for patients with T2DM and CHD, we used the
abovementioned dose of chromium based on previous studies
in T2DM elderly patients [24] and patients with women with
polycystic ovary syndrome [25]. Color, shape, size, and pack-
age of placebos and chromium supplements were identical.
Randomization assignment was conducted using computer-
generated random numbers. Randomization and allocation
were concealed from the investigators and participants until
the final analyses were completed. The randomized allocation
sequence, enrolling of participants, and their allocation to in-
terventions were performed by trained staff at the cardiology
clinic. Compliance with the consumption of placebos and
chromium supplements was performed by examining the cap-
sule containers. To increase compliance, all participants re-
ceived brief daily cell phone reminders to take the supple-
ments. All patients completed 3-day dietary intake records at
weeks 1, 6, and 12 of treatment. For obtaining patients’ nutri-
ent intakes according to 3-day food records, Nutritionist IV
software (First Databank, San Bruno, CA), which was adapted
for Iranian food pattern, was applied. Anthropometric mea-
sures (Seca, Hamburg, Germany) recorded at baseline and
also after the 12-week intervention in the cardiology clinic.
All anthropometric measures were conducted by a trained
nutritionist. In addition, nutritionist was blinded to the ran-
domization assignments.
Outcomes
The homeostasis model of assessment-insulin resistance
(HOMA-IR) and insulin levels were considered as the primary
outcomes, but fasting plasma glucose (FPG), the quantitative
insulin sensitivity check index (QUICKI), serum lipids, and
biomarkers of inflammation and oxidative stress were consid-
ered as secondary outcomes. Fasting blood (10 mL) was taken
at baseline after the 12-week intervention at Kashan Reference
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Laboratory. Insulin levels were measured by ELISA kit
(DiaMetra, Milano, Italy) with inter-assay and intra-assay co-
efficient variances (CVs) below 5%. HOMA-IR and QUICKI
were assessed in accordance with the standard formula [26].
Enzymatic kits (Pars Azmun, Tehran, Iran) were used to esti-
mate fasting plasma glucose (FPG) and lipid variables with
inter- and intra-assay CVs below 5%. Hs-CRP levels were
assessed by an ELISA kit (LDN, Nordhorn, Germany) with
inter- and intra-assay CVs below 7%. Total nitrite by the
Griess assay [27], total antioxidant capacity (TAC) using the
method reported by Benzie and Strain [28], total glutathione
(GSH) byBeutler et al. method [29], andMDA concentrations
were determined by the spectrophotometric test [30] with
inter- and intra-assay CVs below 5%. Systolic (SBP) and di-
astolic blood pressure (DBP) was determined using a sphyg-
momanometer (ALPK2, Zhejiang, China). Blood pressure
values were reported in millimeters of mercury (mmHg).
Statistical Methods and Sample Size
Sample size formula for randomized clinical trial were used,
where type 1 (α) and type 2 errors (β) were 0.05 and 0.20
(power = 80%), respectively. In a previous study [25], 1.61 as
the SD and 1.18 as the change in mean (d) of HOMA-IR were
used. According to the power calculation, in each group, 29
individuals were needed; after allowing for 5 dropouts in each
group, the final sample size was 35 persons in each group.
The Kolmogorov-Smirnov test was used for checking the
normality of data. To determine the differences in anthropo-
metric measures and dietary intakes between treatment
groups, the independent-samples t test was used. Paired-
samples t test was used to detect within-group differences.
Differences in proportions were evaluated by Fisher’s exact
test. Multiple linear regression models were used to evaluate
treatment impacts on study outcomes after adjusting for con-
founding parameters, including baseline levels of each bio-
chemical variable, age, and baseline BMI. The effect sizes
were presented as the mean differences with 95% confidence
intervals. The Pearson chi-square test was applied for compar-
ison of categorical variables. P values < 0.05 were considered
significant. The Statistical Package for Social Science version
18 (SPSS Inc., Chicago, Il, USA) was used for statistical anal-
yses of this trial.
Data Availability The primary data for this study is available
from the authors on direct request.
Results
Among patients in chromium and placebo groups, three par-
ticipants were withdrawn due to personal reasons (Fig. 1).
Finally, sixty-four patients (chromium (n = 32) and placebo
(n = 32)) completed the trial. The compliance rate was high;
two groups took more than 90% of capsules during the trial.
No adverse effects were reported in T2DM patients with CHD
while consuming chromium supplements.
No significant differences were seen between groups re-
garding mean of age, height, baseline, and end-of-trial weight
and BMI (Table 1). Chromium supplementation significantly
reduced body weight (− 0.9 ± 1.6 vs. + 0.1 ± 0.8 kg, P =
0.001) and BMI (− 0.4 ± 0.7 vs. + 0.1 ± 0.3 kg/m2, P =
0.002) compared with the placebo. Furthermore, a significant
within-group reduction in weight (P = 0.003) and BMI (P =
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Fig. 1 Summary of patient flow
diagram
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0.006) was seen in the chromium group. The mean smoking,
taking antidiabetic and antilipidemic agents, hypertension
rate, consumption of angiotensin-converting enzyme inhibi-
tors (ACEI), aldosterone receptor blocker (ARB) drugs, and
blocker drugs (β-blocker and calcium channel blocker) of the
study participants were not statistically different between the
two groups.
Macronutrient and micronutrient supplementation calculat-
ed based on the 3-day food record was not significantly dif-
ferent between the chromium and control groups (data not
shown).
After the 12-week intervention, chromium supplementa-
tion significantly reduced FPG (β − 11.03 mg/dL; 95% CI,
− 18.97, − 3.09; P = 0.007), insulin (β − 1.33 μIU/mL; 95%
CI, − 1.90, − 0.76; P < 0.001), and HOMA-IR (β − 0.44; 95%
CI, − 0.62, − 0.25; P < 0.001) and significantly increased
QUICKI (β 0.007; 95% CI, 0.003, 0.01; P < 0.001) compared
with the placebo (Table 2). In addition, taking chromium led
to a significant reduction in serum hs-CRP (β − 0.49 mg/L;
95% CI, − 0.91, − 0.06; P = 0.02) and plasma MDA levels (β
− 0.22 μmol/L; 95% CI, − 0.35, − 0.10; P = 0.001); also, a
significant rise in TAC (β 84.54 mmol/L; 95% CI, 31.05,
138.02; P = 0.002) was observed in comparison with placebo.
Additionally, chromium administration significantly reduced
DBP (β − 5.01 mmHg; 95% CI, − 9.04, − 0.97; P = 0.01)
compared with the placebo. Chromium supplementation did
not affect triglycerides, VLDL-cholesterol, total cholesterol,
LDL-cholesterol, HDL-cholesterol, and total cholesterol/
HDL-cholesterol ratios, total nitrite, GSH levels, and SBP.
Discussion
In the current study, which to the best of our knowledge is the
first of its kind, we found that the 12-week supplementation of
chromium to diabetic patients with CHD had beneficial im-
pacts on weight, BMI, glycemic control, hs-CRP, TAC,MDA,
and DBP, but did not affect other metabolic profiles.
Chromium supplementation may have an indirect role in
DBP due to its beneficial effect on glycemic control and lipid
profiles. It must be kept in mind that taking antidiabetic and
antilipidemic agents would not influence our findings because
individuals in both intervention and non-intervention groups
were taking antidiabetic and antilipidemic agents. This should
be taken into account in the interpretation of our findings.
However, in the current study, observed changes in glycemic
control, hs-CRP, TAC, MDA, and DBP was statistically sig-
nificant; it was not clinically significant. Long-term interven-
tion and higher dosage of chromium might result in greater
changes in these variables.
Table 1 General characteristics of study participants at baseline study
Placebo group (n = 32) Chromium group (n = 32) P1
Age (years) 60.9 ± 7.7 58.0 ± 8.0 0.14
Height (cm) 160.8 ± 7.5 162.0 ± 9.8 0.58
Gender
Female 15 (46.9%) 17 (53.1%)
Male 17 (53.1%) 15 (46.9%) 0.61†
Weight (kg)
Baseline 77.4 ± 11.9 79.7 ± 13.2 0.45
End-of-trial 77.5 ± 11.9 78.8 ± 12.8 0.68
P2 0.30 0.003
BMI (kg/m2)
Baseline 29.9 ± 3.8 30.4 ± 4.3 0.61
End-of-trial 29.9 ± 3.8 30.0 ± 4.1 0.92
P2 0.29 0.006
Aspirin 80 mg (%) 32 (100) 32 (100) 1.00†
Statin (%) 32 (100) 32 (100) 1.00†
Insulin therapy (%) 10 (31.3) 8 (25.0) 0.57†
Antidiabetic drugs (%)
Monotherpy 17 (68.0) 16 (61.5)
Combination therapy 8 (32.0) 10 (38.5) 0.62†
Data are means ± SDs
1Obtained from independent t test
2 Obtained from paired-samples t test
†Obtained from Fisher’s exact test
316 Farrokhian et al.
Effects on Body Weight, Glycemic Control, and Lipid
Profiles
T2DM is accompanied by insulin resistance and dyslipidemia.
In addit ion, diabetic patients are susceptible for
hyperglycemia-induced oxidative stress and inflammatory sta-
tus which attributed to CHD [2]. Our study showed that chro-
mium supplementation significantly decreased body weight
and BMI in T2DM complicated with CHD. Consistent with
the present data, in a meta-analysis study by Onakpoya et al.
[13], chromium supplementation significantly reduced body
weight in overweight and obese individuals. In addition, a 3-
month chromium supplementation (1000 μg/day) to T2DM
patients attenuated weight gain [31]. Also, chromium supple-
mentation for 6 months (1000 μg/day) to women with PCOS
led to a significant decrease in BMI [32]. However, another
study did not show any significant effect on BMI after 8 weeks
of chromium supplementation (500 μg/day) in patients with
T2DM [33]. Overweight and obesity are associated with insu-
lin resistance and T2DM which accelerate the progression of
CHD and worsen its prognosis [34]. Weight loss in diabetic
and coronary patients ameliorates insulin resistance and
metabolic syndrome components, including dyslipidemia
and hypertension [35, 36]. The beneficial effects of chromium
on body weight may be related to the modulation of energy
expenditure and the reduction of ghrelin response by increas-
ing insulin sensitivity which regulates energy intake [20, 37].
In this research, we found that taking chromium supple-
ments was associated with a decrease in FPG, insulin levels,
and HOMA-IR and an increase in QUICKI without affecting
lipid profiles in diabetic patients with CHD. Similar to our
findings, chromium supplementation at a dosage of 400 μg/
day for 3 months to T2DM patients decreased FPG, circulat-
ing insulin levels and HOMA-IR [38]. In addition, a 4-month
chromium supplementation at a dosage of 600 μg/day to pa-
tients with poorly controlled T2DM improved FPG, while did
not affect lipid variables [39].Moreover, a 16-week chromium
supplementation (400 μg/day) to patients with human immu-
nodeficiency virus infection decreased insulin values and
HOMA-IR and did not influence lipid parameters except for
triglycerides [40]. In support with our study, a 2-week chro-
mium supplementation (100 μg/day) followed by 6 weeks of
chromium supplementation at dosage 200 μg/day did not af-
fect lipid variables in T2DM patients [41]. However, 6 months
Table 2 The effect of chromium supplementation on metabolic status in type 2 diabetic patients with coronary heart disease
Variables Placebo group (n = 32) Chromium group (n = 32) Difference in outcome measures between
chromium and placebo treatment groups1
Baseline Week 12 Baseline Week 12 β (95% CI) P2
FPG (mg/dL) 123.6 ± 36.5 125.6 ± 35.3 129.9 ± 42.5 119.9 ± 33.8 − 11.03 (− 18.97,− 3.09) 0.007
Insulin (μIU/mL) 11.1 ± 3.1 11.1 ± 2.8 11.6 ± 1.5 10.2 ± 1.7 − 1.33 (− 1.90,− 0.76) < 0.001
HOMA-IR 3.4 ± 1.5 3.4 ± 1.5 3.8 ± 1.5 3.3 ± 1.4 − 0.44 (− 0.62,− 0.25) < 0.001
QUICKI 0.32 ± 0.01 0.32 ± 0.01 0.31 ± 0.01 0.32 ± 0.01 0.007 (0.003, 0.01) < 0.001
Triglycerides (mg/dL) 131.0 ± 45.7 133.5 ± 41.9 140.1 ± 42.9 133.4 ± 37.5 − 8.79 (− 18.71, 1.13) 0.08
VLDL-cholesterol (mg/dL) 26.2 ± 9.1 26.7 ± 8.4 28.0 ± 8.6 26.7 ± 7.5 − 1.75 (− 3.74, 0.22) 0.08
Total cholesterol (mg/dL) 160.4 ± 34.8 161.3 ± 35.9 164.5 ± 43.7 166.2 ± 47.5 5.21 (− 11.92, 22.34) 0.54
LDL-cholesterol (mg/dL) 90.6 ± 37.2 92.8 ± 38.0 91.9 ± 39.6 95.3 ± 46.0 5.11 (− 12.00, 22.23) 0.55
HDL-cholesterol (mg/dL) 43.6 ± 6.5 41.9 ± 5.3 44.7 ± 8.9 44.2 ± 8.3 1.43 (− 0.52, 3.40) 0.14
Total cholesterol/HDL-cholesterol ratio 3.7 ± 1.2 3.9 ± 1.1 3.7 ± 0.9 1.4 0.001 (− 0.40, 0.40) 0.99
hs-CRP (mg/L) 4.5 ± 1.9 4.4 ± 1.9 5.2 ± 1.8 4.5 ± 2.6 − 0.49 (− 0.91,− 0.06) 0.02
Total nitrite (μmol/L) 32.8 ± 4.5 32.9 ± 4.3 31.6 ± 4.9 30.8 ± 4.5 − 1.14 (− 2.68, 0.40) 0.14
TAC (mmol/L) 992.0 ± 207.2 998.3 ± 227.9 1064.6 ± 114.1 1146.7 ± 75.8 84.54 (31.05, 138.02) 0.002
GSH (μmol/L) 615.7 ± 136.0 635.5 ± 148.3 655.4 ± 115.5 672.4 ± 109.4 10.02 (− 38.85, 58.89) 0.68
MDA (μmol/L) 2.8 ± 0.5 2.8 ± 0.6 2.7 ± 0.3 2.5 ± 0.2 − 0.22 (− 0.35,− 0.10) 0.001
SBP (mmHg) 129.5 ± 19.1 130.9 ± 18.8 126.6 ± 14.4 125.6 ± 13.7 − 3.65 (− 9.51, 2.21) 0.21
DBP (mmHg) 78.2 ± 10.7 78.9 ± 10.1 76.9 ± 7.2 73.6 ± 7.4 − 5.01 (− 9.04,− 0.97) 0.01
Data are mean ± SDs
1 “Outcomemeasures” refers to the change in values of measures of interest between baseline and week 12. β (difference in the mean outcomes measures
between treatment groups (chromium group = 1 and placebo group = 0))
2 Obtained from multiple regression model (adjusted for baseline values of each biochemical variables, age, and baseline BMI)
DBP diastolic blood pressure, FPG fasting plasma glucose, GSH total glutathione, HOMA-IR homeostasis model of assessment-estimated insulin
resistance, hs-CRP high-sensitivity C-reactive protein,MDAmalondialdehyde, QUICKI quantitative insulin sensitivity check index, SBP systolic blood
pressure, TAC total antioxidant capacity
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of chromium supplementation at dosage 500 μg or 1000 μg/
day did not affect FPG, insulin levels, and HOMA-IR in indi-
viduals at risk for diabetes mellitus [42]. In contrast to our
findings, an 8-week chromium supplementation (200 μg/
day) improved triglycerides and HDL-cholesterol levels
[43]. In patients with T2DM, insulin resistance and glucose
disturbances are correlated with vascular stiffness and athero-
sclerosis [44]. Chromium is a central part of chromodulin,
which involved in the insulin action [45, 46]. It also enhances
beta cell sensitivity and increases the number of insulin recep-
tors [45]. Moreover, chromium decreases protein tyrosine
phosphatase 1B activity, increases mitogen-activated protein
kinase function and insulin receptor phosphorylation, and pro-
motes the translocation of GLUT4 in cell membrane, which in
turn improves insulin sensitivity and glucose uptake [19, 47].
Effects on Biomarkers of Inflammation and Oxidative
Stress
The findings of present study showed that consuming chromi-
um supplements for 12 weeks led to a significant decrease in
hs-CRP and MDA levels and a significant increase in TAC in
diabetic individuals with CHD. In accordance with our find-
ings, several animal investigations have shown that chromium
administration led to a significant decrease in MDA and CRP
concentrations [48–50]. In addition, we have previously re-
ported that an 8-week chromium supplementation at a dosage
of 200 μg/day to women with PCOS candidate for in vitro
fertilization increased TAC and reduced MDA levels [51].
Moreover, supplementation with chromium, zinc, and magne-
sium for 24 weeks decreased CRP levels in patients with met-
abolic syndrome [52]. In contrast to the results of present
study, a 16-week chromium supplementation (100 μg/day)
to non-diabetic adults with obesity did not affect CRP and
other inflammatory markers [14]. In diabetic patients, oxida-
tive stress and elevated inflammatory mediators such as CRP
are associated with endothelial dysfunction and the progres-
sion of macrovascular disease [53]. In addition, a significant
positive correlation has been reported between circulating
MDA levels and FPG in T2DM complicated with CHD
[54]. Chromium may act as an indirect antioxidant via de-
creasing insulin levels and preventing the auto-oxidation of
glucose [55]. In vitro exposure with chromium decreased lipid
peroxidation in red blood cells exposed to high glucose, which
in turn reduced oxidative stress [56]. It also contributes in anti-
inflammatory process by modulation the activity of NF-kB
[21].
The limitations of this study were few. Due to funding
limitations, we did not measure chromium and HbA1c levels
before and after the intervention. The next limitation was that
gene expression related to lipid, insulin, inflammation, and
oxidative damage in patients with diabetes who underwent
CHD was not evaluated.
Conclusions
Overall, the 12-week supplementation of chromium to diabet-
ic patients with CHD had beneficial impacts on weight, BMI,
glycemic control, hs-CRP, TAC, MDA, and DBP, but did not
affect other metabolic profiles.
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